Physician profile
Muhammad T Bashir
NPI 1720081342
$37,979.65
in general payments reported to CMS, 2019-2025
21 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $2,922 · 2021: $11K · 2022: $23K · 2023: $348 · 2024: $520 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.41 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20,869.62 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $15,103.53 | 2019-2023 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $392.39 | 2020-2025 | Jynarque |
| Amgen INC. | $201.10 | 2020-2022 | |
| Daiichi Sankyo INC. | $175.78 | 2020-2024 | Injectafer |
| Kyowa Kirin, INC. | $174.21 | 2024-2025 | Crysvita |
| Travere Therapeutics, INC. | $173.78 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $164.25 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $145.16 | 2021-2024 | Velphoro |
| Mallinckrodt Hospital Products INC. | $124.38 | 2022-2024 | Acthar |
| Vifor Pharma, INC. | $98.41 | 2019-2023 | Veltassa |
| Glaxosmithkline, LLC. | $82.89 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.41 | 2022-2024 | Takhzyro |
| Calliditas Therapeutics US INC. | $53.36 | 2022-2025 | Tarpeyo |
| Abbvie INC. | $27.06 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.48 | 2024 | |
| Pfizer INC. | $26.03 | 2023 | |
| Sun Pharmaceutical Industries INC. | $20.43 | 2020 | |
| Genzyme Corporation | $20.05 | 2022 | |
| Apellis Pharmaceuticals, INC. | $15.03 | 2025 | |
| Akebia Therapeutics INC | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.